All patients
age >= 55 yr age >= 60 yr age >= 65 yr delta variant (B.1.617.2, Indian) elderly (typically over 65yr) immunodepression omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC
first booster dose in COVID-19 prophylaxis (excluding children) - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results Arbel, 2021 0.10 [0.07; 0.14]
Arbel / Magen, 2022 (REV) 4.55 [3.54; 5.83]
Barda, 2021 0.19 [0.05; 0.70]
McConeghy, 2022 0.03 [0.01; 0.10]
0.23 [0.02 ; 3.23 ] Arbel, 2021, Arbel / Magen, 2022 (REV), Barda, 2021, McConeghy, 2022 4 99% 843,208 low not evaluable deaths (time to event analysis only)detailed results Arbel / Magen, 2022 (REV) 4.55 [3.54; 5.83]
4.55 [3.54 ; 5.83 ] Arbel / Magen, 2022 (REV) 1 0% NA not evaluable hospitalization or deathdetailed results Abu-Raddad, 2022 0.23 [0.12; 0.44]
McConeghy, 2022 0.18 [0.07; 0.49]
0.21 [0.12 ; 0.37 ] Abu-Raddad, 2022, McConeghy, 2022 2 0% NA not evaluable confirmed COVID (any severity)detailed results Abu-Raddad, 2022 0.51 [0.49; 0.54]
Accorsi, 2022 0.35 [0.33; 0.38]
Arbel / Magen, 2022 (REV) 1.82 [1.77; 1.87]
Bar-On, 2021 0.09 [0.08; 0.10]
Bar-On, 2022 (REV) 2.13 [2.06; 2.19]
C4591031- first boost, 2021 0.05 [0.02; 0.13]
Cohen, 2022 0.56 [0.50; 0.63]
COVI3, 2022 0.07 [0.02; 0.22]
Kislaya, 2022 0.36 [0.20; 0.64]
Mattiuzzi, 2022 0.35 [0.32; 0.38]
McConeghy, 2022 0.49 [0.34; 0.70]
Patalon, 2021 0.21 [0.16; 0.28]
Patalon, 2022 0.15 [0.14; 0.17]
Regev-Yochay (Comirnaty), 2022 (REV) 1.43 [0.92; 2.22]
Regev-Yochay (Spikevax), 2022 (REV) 1.12 [0.70; 1.79]
Tan, 2022 0.27 [0.26; 0.29]
0.38 [0.23 ; 0.64 ] Abu-Raddad, 2022, Accorsi, 2022, Arbel / Magen, 2022 (REV), Bar-On, 2021, Bar-On, 2022 (REV), C4591031- first boost, 2021, Cohen, 2022, COVI3, 2022, Kislaya, 2022, Mattiuzzi, 2022, McConeghy, 2022, Patalon, 2021, Patalon, 2022, Regev-Yochay (Comirnaty), 2022 (REV), Regev-Yochay (Spikevax), 2022 (REV), Tan, 2022 16 100% 40,249 NA critical hospitalizationdetailed results Arbel / Magen, 2022 (REV) 3.13 [2.49; 3.92]
Barda, 2021 0.07 [0.04; 0.14]
Lauring, 2022 0.06 [0.05; 0.08]
Mattiuzzi, 2022 0.31 [0.22; 0.44]
McConeghy, 2022 0.52 [0.08; 3.59]
Patalon, 2022 0.08 [0.05; 0.13]
Tan, 2022 0.05 [0.03; 0.08]
Tenforde, 2022 0.18 [0.09; 0.35]
0.18 [0.04 ; 0.75 ] Arbel / Magen, 2022 (REV), Barda, 2021, Lauring, 2022, Mattiuzzi, 2022, McConeghy, 2022, Patalon, 2022, Tan, 2022, Tenforde, 2022 8 99% 398,920 NA not evaluable symptomatic Covid-19detailed results Abu-Raddad, 2022 0.51 [0.49; 0.54]
Accorsi, 2022 0.35 [0.33; 0.38]
Arbel / Magen, 2022 (REV) 2.22 [2.10; 2.35]
Bar-On, 2022 (REV) 2.94 [2.37; 3.64]
COVI3, 2022 0.07 [0.02; 0.25]
Regev-Yochay (Comirnaty), 2022 (REV) 1.75 [1.06; 2.90]
Regev-Yochay (Spikevax), 2022 (REV) 1.45 [0.84; 2.49]
0.88 [0.42 ; 1.85 ] Abu-Raddad, 2022, Accorsi, 2022, Arbel / Magen, 2022 (REV), Bar-On, 2022 (REV), COVI3, 2022, Regev-Yochay (Comirnaty), 2022 (REV), Regev-Yochay (Spikevax), 2022 (REV) 7 100% 513 NA not evaluable ICU admissiondetailed results Mattiuzzi, 2022 0.33 [0.08; 1.36]
0.33 [0.08 ; 1.36 ] Mattiuzzi, 2022 1 0% NA not evaluable severe COVID-19 (FDA definition)detailed results C4591031- first boost, 2021 0.25 [0.01; 5.50]
0.25 [0.01 ; 5.50 ] C4591031- first boost, 2021 1 0% 10,125 NA not evaluable severe COVID-19 occurrencedetailed results Arbel / Magen, 2022 (REV) 2.63 [1.90; 3.65]
Bar-On, 2021 0.06 [0.04; 0.10]
Bar-On, 2022 (REV) 2.94 [2.37; 3.64]
Barda, 2021 0.08 [0.03; 0.20]
C4591031- first boost, 2021 0.25 [0.01; 5.50]
Tan, 2022 0.05 [0.03; 0.08]
0.29 [0.05 ; 1.61 ] Arbel / Magen, 2022 (REV), Bar-On, 2021, Bar-On, 2022 (REV), Barda, 2021, C4591031- first boost, 2021, Tan, 2022 6 99% 10,125 NA not evaluable arrhythmiadetailed results C4591031- first boost, 2021 1.99 [0.07; 59.22]
1.99 [0.07 ; 59.22 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable hypertensiondetailed results C4591031- first boost, 2021 0.50 [0.02; 14.80]
0.50 [0.02 ; 14.80 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable Myocardial infarction detailed results C4591031- first boost, 2021 0.74 [0.17; 3.33]
0.74 [0.17 ; 3.33 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable pulmonary embolismdetailed results C4591031- first boost, 2021 0.17 [0.01; 3.30]
0.17 [0.01 ; 3.30 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable stroke (non-specific, hemorrhagic, and ischemic)detailed results C4591031- first boost, 2021 0.99 [0.06; 15.88]
0.99 [0.06 ; 15.88 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable cerebral venous sinus thrombosis (CVST)detailed results C4591031- first boost, 2021 0.50 [0.02; 14.80]
0.50 [0.02 ; 14.80 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable appendicitisdetailed results C4591031- first boost, 2021 3.97 [0.18; 88.14]
3.97 [0.18 ; 88.14 ] C4591031- first boost, 2021 1 0% 10,075 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-13 03:29 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 89
- treatments: 1088,1331,1330,1329,1344,1328,1327
- roots T: 290
